Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „Keytruda“
Suchtreffer
Begriffe & Kennungen
Keytruda · 4.8 · Immune-mediated pneumonitis Pneumonitis occurred in 324 (4.2%) patients, including Grade 2, 3, 4 or 5 cases in
Eintrag öffnenKeytruda · 4.8 · Immune-mediated skin adverse reactions Immune-mediated severe skin reactions occurred in 130 (1.7%) patients,
Eintrag öffnenKeytruda · 4.8 · Immune-mediated skin adverse reactions Immune-mediated severe skin reactions occurred in 130 (1.7%) patients,
Eintrag öffnenKeytruda · 4.8 · Immunogenicity In a clinical study in patients treated with subcutaneous administration of KEYTRUDA solution f
Eintrag öffnenKeytruda · 4.8 · Immunogenicity In clinical studies in patients treated with pembrolizumab 2 mg/kg bw every three weeks, 200 mg
Eintrag öffnenKeytruda · 4.8 · In patients treated with pembrolizumab in combination with axitinib or lenvatinib, the proportion of patients
Eintrag öffnenKeytruda · 4.8 · In patients treated with pembrolizumab in combination with chemotherapy, RT or CRT, the proportion of patients
Eintrag öffnenKeytruda · 4.8 · In patients treated with pembrolizumab in combination with chemotherapy, RT or CRT, the proportion of patients
Eintrag öffnenKeytruda · 4.8 · In patients with NSCLC, pneumonitis occurred in 230 (6.1%), including Grade 2, 3, 4 or 5 cases in 103 (2.7%),
Eintrag öffnenKeytruda · 4.8 · In patients with NSCLC, pneumonitis occurred in 230 (6.1%), including Grade 2, 3, 4 or 5 cases in 103 (2.7%),
Eintrag öffnenKeytruda · 4.8 · Intravenous formulation The safety of pembrolizumab as monotherapy has been evaluated in 161 paediatric patien
Eintrag öffnenKeytruda · 4.8 · KEYTRUDA solution for injection in MK-3475A-D77 and includes injection site reaction, injection site erythema,
Eintrag öffnenKeytruda · 4.8 · Laboratory abnormalities In patients treated with pembrolizumab monotherapy, the proportion of patients who ex
Eintrag öffnenKeytruda · 4.8 · Laboratory abnormalities In patients treated with pembrolizumab monotherapy, the proportion of patients who ex
Eintrag öffnenKeytruda · 4.8 · MedDRA SOC Monotherapy In combination with In combination with and frequency chemotherapy, axitinib or lenvati
Eintrag öffnenKeytruda · 4.8 · MedDRA SOC Monotherapy In combination with In combination with and frequency chemotherapy, axitinib or lenvati
Eintrag öffnenKeytruda · 4.8 · Of 14 patients in KEYNOTE-204 who proceeded to allogeneic HSCT after treatment with pembrolizumab, 8 patients
Eintrag öffnenKeytruda · 4.8 · Of 14 patients in KEYNOTE-204 who proceeded to allogeneic HSCT after treatment with pembrolizumab, 8 patients
Eintrag öffnenKeytruda · 4.8 · Of 32 patients in KEYNOTE-087 who proceeded to allogeneic HSCT after treatment with pembrolizumab, 16 patients
Eintrag öffnenKeytruda · 4.8 · Of 32 patients in KEYNOTE-087 who proceeded to allogeneic HSCT after treatment with pembrolizumab, 16 patients
Eintrag öffnen